Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery
Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cardiac Output, Low; Coronary Disease
Intervention: Liberal dobutamine protocol (Drug); Restrictive dobutamine protocol (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: University of Sao Paulo
Summary
Inotropic agents are usually administered in the postoperative period after cardiac surgery.
In most cases, dobutamine is administered routinely, for the probable occurrence of
myocardial dysfunction after cardiopulmonary bypass or a low cardiac output with minimal
evidence of altered tissue perfusion.
Recent data show that inotropic agents are used in 35-52% of cardiac surgeries in the
perioperative period. However, the use of inotropic agents may be associated with adverse
events, including myocardial ischemia, by elevation in myocardial oxygen consumption and the
imbalance between supply and consumption, and tachyarrhythmias (atrial fibrillation, sinus
tachycardia, ventricular tachyarrhythmias), primarily due to the β1-adrenergic effect.
This study is a non-inferiority clinical randomized study aiming to compare the use of
dobutamine in a liberal strategy (in all patients at the time of withdrawal of CPB) with a
restrictive strategy (based on clinical and hemodynamic evidence of low cardiac output
syndrome associated with altered tissue perfusion). Our primary hypothesis is that the
restrictive use of dobutamine is as safe and effective as the liberal one.
Clinical Details
Official title: Liberal Versus Restrictive Dobutamine in Cardiac Surgery (DOBUTACS): a Prospective Randomized Non-inferiority Clinical Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Combined endpoint of arrhythmias (ventricular and supraventricular), acute myocardial infarction, stroke or transient ischemic attack, low-output syndrome, cardiogenic shock and death from all causes within 30 days after cardiac surgery
Secondary outcome: Mortality rateAcute myocardial infarction incidence Stroke incidence Low cardiac output syndrome Cardiogenic shock Cardiac arrhythmias ICU and hospital length of stay Days free of mechanical ventilation Severe sepsis and septic shock SOFA score within 72 hours
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients undergoing cardiac surgery of coronary artery bypass graft (CABG) with
cardiopulmonary bypass;
- Age equal or greater than 18 years;
- Written informed consent.
Exclusion Criteria:
- Previous ventricular dysfunction (ejection fraction lower than 50%)
- Sustained supraventricular or ventricular arrhythmias;
- Cardiogenic shock or need for inotropes before surgery;
- Immediate need of ventricular assist device or intraaortic balloon after CPB;
- Combined procedure;
- Pregnancy;
- Participation in another study.
Locations and Contacts
Heart Institute, Sao Paulo, SP 05403000, Brazil
Additional Information
Starting date: February 2015
Last updated: February 6, 2015
|